Alnylam Launches STAR, A Symptom Tracker App to Help People with ATTR Amyloidosis Track Their Disease Symptoms

Alnylam Launches STAR, A Symptom Tracker App to Help People with ATTR Amyloidosis Track Their Disease Symptoms

- New app allows for simple and quick recording of evolving symptoms to encourage more confident discussions with healthcare teams

Maidenhead, 12th October 2021 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today launched STAR, a digital symptom tracker to support people with ATTR amyloidosis and their families in the UK. The app features a range of simple-to-use functions that allow patients to record their symptoms quickly and share timely, accurate information with their doctor during or in-between consultations to support more impactful conversations. STAR is available now on the App Store and Google Play. 

“ATTR amyloidosis is a rapidly progressive multisystem disease that is characterized by an increasing complexity and severity of symptoms,” said Professor Philip Hawkins, Professor of Medicine, National Amyloidosis Centre, United Kingdom. “Because the disease can evolve over time, it is important for patients to accurately track any changes in their symptoms. This new app will help people living with ATTR amyloidosis track their disease progression, while offering healthcare teams a more accurate picture of their patients’ disease.”

The symptoms of ATTR amyloidosis vary from person to person and may affect multiple parts of the body, including the heart, nerves, gastrointestinal tract and other organs. Designed in collaboration with patients and with input from healthcare professionals, STAR provides a tracking system that helps users recognize and understand these complex symptoms, as well as note any changes between healthcare visits.

“Alnylam is dedicated to working with both healthcare professionals and patients to advance best practice in the management of rare diseases such as ATTR amyloidosis,” said Dr Dinesh Kumar, Medical Director for UK and Ireland, Alnylam Pharmaceuticals. “STAR was designed to help patients better understand their condition and its impact on their quality of life, including their ability to carry out day-to-day activities, mood, energy levels, and relationships with family and friends. Our goal is to empower patients to have greater control of their health and wellbeing, and we hope that tools such as this digital symptom tracker will enable them to achieve that.”

The free app is currently available for mobile phones on the App Store and Google Play in English as well as French, Spanish, Italian, German, Swedish, Danish, Portuguese and Dutch. A tablet format will be launched later this year. 

Disclaimer
The app is not a medical device and should not be used to make a medical diagnosis. It is not intended as a disease monitoring tool or as a symptoms checker. 

To have symptoms checked, users are advised to talk to their healthcare professional. Users are advised to seek the advice of a medical professional if they are concerned about their health.

About STAR, the Digital Symptom Tracker
STAR is a digital symptom tracker that has been designed by patients and healthcare professionals for people with ATTR amyloidosis and their families. The app aims to support routine recording of patients’ symptoms, which can evolve or change over time, between visits to their doctor. This allows them to capture and share information on the changing pattern of their symptoms.The features of the app offer an easy-to-navigate menu with the most common symptoms so that patients can:
• Identify and record the complete picture of their symptoms listed by body part.
• Track symptom changes with a simple click, whenever it is most convenient for them.
• Make diary entries on the impact of each symptom on day-to-day activities, mood, energy 
levels, and relationships with family and friends
• Have the option to share with their doctor in confidence, a summary of any symptom 
changes and their impact over time.
• Personalize the app for the symptoms that matter most to them.

About ATTR Amyloidosis 
Transthyretin-mediated (ATTR) amyloidosis is a rare, rapidly progressive, debilitating disease caused by misfolded transthyretin (TTR) proteins which accumulate as amyloid fibrils in multiple tissues including the nerves, heart, and gastrointestinal (GI) tract. There are two different types of ATTR amyloidosis – Hereditary ATTR (hATTR) amyloidosis, caused by a TTR gene variant, and Wild-type ATTR amyloidosis (wtATTR), which occurs without a TTR gene variant. hATTR amyloidosis affects approximately 50,000 people worldwide, while wtATTR amyloidosis is estimated to impact 200,000 – 300,000 people worldwide. 

About Alnylam Pharmaceuticals
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. In Europe and the US, Alnylam has a commercial portfolio of three  RNAi therapeutic products. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

Job bag: TTR02-UK-00089
Date of preparation: July 2021